3种治疗急性缺血性脑卒中药的最小成本分析

Cost-minimization Analysis of 3 Types of Drugs for Acute Ischemic Stroke

目的:对3种治疗急性缺血性脑卒中药进行药物经济学评价。方法:95例急性缺血性脑卒中患者按照不同药物治疗方案分为3组,分别给予巴曲酶(降纤组)、阿加曲班(抗凝组)、阿替普酶(溶栓组)治疗,进行最小成本分析。结果:降纤组、抗凝组、溶栓组的总有效率分别为88.89%、85.00%、94.74%(P>0.05),人均治疗总成本分别为13098.27、15477.96、21040.86元(P<0.05)。结论:降纤组方案较经济。

OBJECTIVE： To evaluate the pharrnacoeconomic efficacy of 3 types of drugs for acute ischemic stroke. METHODS： 95 patients with acute ischemic stroke were administered with batroxobin（defibrase group）, argatroba（anticoagulant group）, alteplase （thrombolysis group）. Cost-minimization analysis was applied to analyze the therapeutic effects and costs. RESULTS： The total costs of 3 groups were 13 098.27 yuan, 15 477.96 yuan and 21 040.86 yuan, respectively （P〈0.05）. The total effective rates were 88.89%, 85.00% and 94.74% （P〉0.05）. CONCLUSION： In terms of pharmacoeconomics, defibrase group is superior to other 2 groups.